Creo Medical has provided a trading update for the six-months to 30 June 2023, noting that trading is in-line with management's expectations and the company is on track to meet its 2023 objectives. For H1/23, group revenues are expected to be up 15% to £15.7m, including £0.9m of core technology sales (FY22A: £0.9m). The use of the core technology was driven by increased confirmed users (115 at period end versus 80 at the end of 2022), more high-volume users, the launch of the slimmer Speedboat I ....
